Prostate Cancer Very Low Risk
Reviewed by Oncology Team, HealOnco | Last updated: 2026-04
What Very Low Risk Means
Stage T1c, Gleason ≤6, PSA <10 ng/mL, <3 positive cores with <50% core involvement
Treatment Approach for Very Low Risk
Active surveillance preferred. Annual PSA, DRE, repeat biopsy in 1–2 years.
Survival Rates and Prognosis
The 5-year survival rate for prostate cancer at Very Low Risk is approximately 99%+ (10-yr: 98%+). Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Low Risk | 98%+ (10-yr: 95%) | Active surveillance or definitive therapy (RARP or radiation). Discuss 10-year… |
| Intermediate Risk | 95% (10-yr: 88%–92%) | Definitive therapy: RARP with or without pelvic lymph node dissection, or EBRT… |
| High Risk | 88%–93% (10-yr: 75%–85%) | Definitive therapy + ADT. EBRT – 24–36 months ADT preferred if fit…. |
| Very High Risk | 70%–85% (10-yr: 55%–75%) | Aggressive systemic therapy. EBRT – 36+ months ADT with or without… |
| Metastatic Hormone-Sensitive (mHSPC) | 40%–60% (10-yr: 10%–25%) | Upfront ADT + docetaxel (STAMPEDE/CHAARTED trials showed docetaxel improves… |
| Metastatic Castration-Resistant (mCRPC) | 15%–30% (10-yr: <10%) | Sequence of hormone therapies (abiraterone, enzalutamide, apalutamide) or… |
Prostate Cancer Treatment in Top Cities
Diagnosed with Very Low Risk Prostate Cancer?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free Consultation